FDA Estrogen Guidance Recommends Labeling Changes On Dementia Risk
Executive Summary
FDA is recommending hormone replacement therapy class labeling changes to include new dementia risk information on estrogen-alone therapy in a 1draft guidance on noncontraceptive estrogen drug products